CD318-CAR-T cells therapy (University Hospital Tuebingen)

N/A

Report date: 2025/09/04 20:00:08

Base Information

Drug NameCD318-CAR-T cells therapy (University Hospital Tuebingen)

Drug Alias NameResCPa

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionCUB domain-containing protein 1 modulatorsT lymphocyte replacements

TargetsCUB domain-containing protein 1

Therapy Area/IndicationsPancreatic NeoplasmsCarcinoma, Pancreatic Ductal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Hospital Tuebingen

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Hospital Tuebingen

Inactive CompaniesN/A

Active IndicationsPancreatic NeoplasmsCarcinoma, Pancreatic Ductal

Inactive IndicationsN/A

Other Information

ATC CodeN/A